One-year outcome after CRT implantation in NYHA class IV in comparison to NYHA class III patients

go back to reference Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Török T, Linde C, REVERSE Study Group (2009) Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 54(20):1837-46PubMedCrossRef Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Török T, Linde C, REVERSE Study Group (2009) Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 54(20):1837-46PubMedCrossRef

go back to reference Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338PubMedCrossRef Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338PubMedCrossRef

go back to reference Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization-defibrillation for ambulatory heart failure trial investigators (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385–2395PubMedCrossRef Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization-defibrillation for ambulatory heart failure trial investigators (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385–2395PubMedCrossRef

go back to reference Bristow MR, Saxon LA, Boehmer J, Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) investigators (2004) Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150PubMedCrossRef Bristow MR, Saxon LA, Boehmer J, Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) investigators (2004) Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150PubMedCrossRef

go back to reference Cleland JGF, Daubert J-C, Erdmann E, Cardiac resynchronization heart failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 352:1539-49PubMedCrossRef Cleland JGF, Daubert J-C, Erdmann E, Cardiac resynchronization heart failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 352:1539-49PubMedCrossRef

go back to reference Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, ESC Committee for Practice Guidelines, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Tendera M, Anker SD, Blanc JJ, Gasparini M, Hoes AW, Israel CW, Kalarus Z, Merkely B, Swedberg K, Camm AJ (2010) Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace 12:1526-36PubMedCrossRef Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, ESC Committee for Practice Guidelines, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Tendera M, Anker SD, Blanc JJ, Gasparini M, Hoes AW, Israel CW, Kalarus Z, Merkely B, Swedberg K, Camm AJ (2010) Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace 12:1526-36PubMedCrossRef

go back to reference Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M (2007) Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 115:204–212PubMedCrossRef Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M (2007) Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 115:204–212PubMedCrossRef

go back to reference Castel MA, Magnani S, Mont L, Roig E, Tamborero D, Méndez-Zurita F, Femenia JF, Tolosana JM, Pérez-Villa F, Brugada J (2010) Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace 12:1136–1140PubMedCrossRef Castel MA, Magnani S, Mont L, Roig E, Tamborero D, Méndez-Zurita F, Femenia JF, Tolosana JM, Pérez-Villa F, Brugada J (2010) Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace 12:1136–1140PubMedCrossRef

go back to reference Vidal B, Delgado V, Mont L, Poyatos S, Silva E, Angeles Castel M, Tolosana JM, Berruezo A, Brugada J, Sitges M (2010) Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. Eur J Heart Fail 12:283–287PubMedCrossRef Vidal B, Delgado V, Mont L, Poyatos S, Silva E, Angeles Castel M, Tolosana JM, Berruezo A, Brugada J, Sitges M (2010) Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. Eur J Heart Fail 12:283–287PubMedCrossRef

go back to reference Padeletti L, Muto C, Maounis T, Schuchert A, Bongiorni MG, Frank R, Vesterlund T, Brachmann J, Vicentini A, Jauvert G, Tadeo G, Gras D, Lisi F, Dello Russo A, Rey JL, Boulogne E, Ricciardi G (2008) Management of atrial fibrillation suppression in AF-HF comorbidity therapy study group. atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial. Am Heart J 156:520–526PubMedCrossRef Padeletti L, Muto C, Maounis T, Schuchert A, Bongiorni MG, Frank R, Vesterlund T, Brachmann J, Vicentini A, Jauvert G, Tadeo G, Gras D, Lisi F, Dello Russo A, Rey JL, Boulogne E, Ricciardi G (2008) Management of atrial fibrillation suppression in AF-HF comorbidity therapy study group. atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial. Am Heart J 156:520–526PubMedCrossRef

go back to reference Lehmann MH, Aaronson KD (2006) CRT-D therapy in heart failure: how much do NYHA class IV patients benefit? J Cardiovasc Electrophysiol 17:491–494PubMedCrossRef Lehmann MH, Aaronson KD (2006) CRT-D therapy in heart failure: how much do NYHA class IV patients benefit? J Cardiovasc Electrophysiol 17:491–494PubMedCrossRef

go back to reference Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J (2009) The European cardiac resynchronization therapy survey. Eur Heart J 30:2450–2460PubMedCrossRef Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J (2009) The European cardiac resynchronization therapy survey. Eur Heart J 30:2450–2460PubMedCrossRef

go back to reference Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Störk S (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German competence network heart failure. Clin Res Cardiol 101(4):263–272. doi:10.1007/s00392-011-0388-y PubMedCrossRef Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Störk S (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German competence network heart failure. Clin Res Cardiol 101(4):263–272. doi:10.​1007/​s00392-011-0388-y PubMedCrossRef

go back to reference Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101(1):1–10PubMedCrossRef Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101(1):1–10PubMedCrossRef

go back to reference Schuchert A (2005) Atrial fibrillation and heart failure comorbidity. Minerva Cardioangiol 53:299–311PubMed Schuchert A (2005) Atrial fibrillation and heart failure comorbidity. Minerva Cardioangiol 53:299–311PubMed

go back to reference Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA (2009) Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. JACC 53:355–360PubMedCrossRef Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA (2009) Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. JACC 53:355–360PubMedCrossRef

go back to reference Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, Verboven Y, Tavazzi L (2008) Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol 52:438–445PubMedCrossRef Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, Verboven Y, Tavazzi L (2008) Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol 52:438–445PubMedCrossRef

go back to reference Bai R, di Biase L, Elayi C, Ching CK, Barrett C, Phillips K, Lim P, Patel D, Callahan T, Martin DO, Arruba M, Schweikert R, Saliba W, Wilkoff B, Natale A (2008) Mortality of heart failure after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol 19:1259–1265PubMedCrossRef Bai R, di Biase L, Elayi C, Ching CK, Barrett C, Phillips K, Lim P, Patel D, Callahan T, Martin DO, Arruba M, Schweikert R, Saliba W, Wilkoff B, Natale A (2008) Mortality of heart failure after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol 19:1259–1265PubMedCrossRef

go back to reference van Bommel RJ, van Rijnsoever E, Borleffs CJ, Delgado V, Marsan NA, Bertini M, Schalij MJ, Bax JJ (2010) Effect of cardiac resynchronization therapy in patients with New York Heart Association functional class IV heart failure. Am J Cardiol 106:1146–1151PubMedCrossRef van Bommel RJ, van Rijnsoever E, Borleffs CJ, Delgado V, Marsan NA, Bertini M, Schalij MJ, Bax JJ (2010) Effect of cardiac resynchronization therapy in patients with New York Heart Association functional class IV heart failure. Am J Cardiol 106:1146–1151PubMedCrossRef

go back to reference Becker M, Erdmann N, Stegemann E, Benke D, Schauerte PN, Schaefer WM, Autschbach R, Kelm M, Koch KC (2008) Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transpl 27:746–752CrossRef Becker M, Erdmann N, Stegemann E, Benke D, Schauerte PN, Schaefer WM, Autschbach R, Kelm M, Koch KC (2008) Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transpl 27:746–752CrossRef

go back to reference Herweg B, Ilercil A, Cutro R, Dewhurst R, Krishnan S, Weston M, Barold SS (2007) Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Am J Cardiol 100:90–93PubMedCrossRef Herweg B, Ilercil A, Cutro R, Dewhurst R, Krishnan S, Weston M, Barold SS (2007) Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Am J Cardiol 100:90–93PubMedCrossRef